A Phase II Trial of the Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Patients With Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST)
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 11 Dec 2017
At a glance
- Drugs Selumetinib (Primary)
- Indications Gastrointestinal stromal tumours; Neurofibromatoses
- Focus Therapeutic Use
- 07 Dec 2017 Planned initiation date changed from 1 Dec 2017 to 13 Dec 2017.
- 25 Nov 2017 Planned initiation date changed from 30 Nov 2017 to 1 Dec 2017.
- 22 Nov 2017 Status changed from not yet recruiting to recruiting.